This page is presented for educational purposes and is not meant to describe any Novo Nordisk products.
For nearly a century, Novo Nordisk has combined drug discovery with technology to turn science into treatments for the patients we serve.
The story begins with Nobel-prize winning physiologist Dr. August Krogh and his belief that anyone who suffered from diabetes, including his wife Marie, should have access to insulin.
Inspired by his wife, Dr. Krogh founded Nordisk Insulinlaboratorium in 1923 and marketed the first insulin for patients. Marie was the first beneficiary – and our first patient.
Two years later, another company – Novo Terapeutisk Laboratorium – was born and began producing "Insulin Novo" and a unique syringe.
Over the decades, these 2 companies grew to be global leaders in insulin production and other areas. In 1989, Novo and Nordisk joined forces to become Novo Nordisk.
Our founders could not have foreseen the global pandemic we face today. But our mission remains the same: to provide care and treatment for people with diabetes around the world and to put patient needs at the center of everything we do.
As a world leader in diabetes care, Novo Nordisk’s greatest contribution to society is our commitment to bringing value to patients and healthcare professionals through innovation. However, diabetes is not our only focus. Our innovative work in hemophilia, growth hormone disorders, and women’s health is driven by this same commitment.
Our global vision is to defeat diabetes in our lifetime - a truly unique and ambitious endeavor, but we believe that by actively promoting collaboration between all parties in the healthcare system, we can achieve our common goals.
To learn more, please visit us at novonordisk-US.com.
Changing How We Care
Changing How We Work
Changing the Global Agenda
Changing the Course
We are dedicated to diabetes — how it is treated, how it is viewed around the world, and how the future of this disease plays out.
At Novo Nordisk, we are committed to fighting the diabetes pandemic in many ways, and the resources we dedicate to diabetes research are unparalleled in the industry.
Novo Nordisk was one of the first companies to introduce insulin to the world, and since then we have helped change how diabetes is treated. In 2012, we opened our new type 1 diabetes research center in Seattle, WA to accelerate the process of finding new treatments for people living with the disease.
For those with diabetes who have difficulty affording their medication, Novo Nordisk’s Diabetes Patient Assistance Program (PAP) donates free products to those who financially qualify. For more information about the Novo Nordisk Diabetes PAP, visit novonordiskpap.com.
At Novo Nordisk we believe action defines leadership. We have the potential and responsibility to make a difference for people with diabetes, facilitating change, in addition to providing treatments.
Established by Novo Nordisk, the World Diabetes Foundation is dedicated to supporting prevention and treatment of diabetes with 300 programs in over 100 countries. To learn more, visit worlddiabetesfoundation.org.
An online tool that provides healthcare professionals, patient organizations, politicians, institutions, and media with valuable information on the progress of diabetes and diabetes care. To utilize the tool, visit changingdiabetesbarometer.com.
Inspired by our patient-centric philosophy, we support programs that provide educational resources to empower patients and healthcare providers.
This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
For nearly a century, Novo Nordisk has focused on diabetes care and areas of unmet medical needs, always keeping the patient at the center of everything we do. We believe that to do what is good for the patient, you must do what is good for the world. This is expressed through our Triple Bottom Line principles — a commitment to social responsibility, environmental soundness, and economic viability:
From Our First Patient to Today’s Innovation
Novo Nordisk is Committed to Diabetes
Triple Bottom Line: Responsible Business is Healthy Business